Researcher Profile
Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Center/Program
Department
Medical Oncology/Hematologic Malignancies
Interest
Leukemia, myelodysplastic syndromes, myeloproliferative disorders
Area of Research
Treating Leukemias, Myelodysplasia, and Myeloproliferative Disorders
Contact Information
Daniel J. DeAngelo, MD, PhDDana-Farber Cancer Institute
44 Binney Street
Dana D1B30
Boston, MA 02115
Office phone: (617) 582-8410
Fax: (617) 632-6771
E-mail: ddeangelo@partners.org
Preferred contact method: office phone
Research
The Adult Leukemia Group is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplastic syndrome (MDS), and other stem cell hematopoietic disorders. Our clinical research centers around phase I, II, and III clinical trials in these patients.
We recently studied a series of patients with idiopathic hypereosinophilic syndrome (IHES). In collaboration with Drs. Cools and Gilliland, we identified a target gene, the FIP1L1-PDGFRA fusion gene, which is a consequence of an interstitial chromosomal deletion. This finding has led to the explanation of the molecular basis of IHES.
Our group is currently working on the development of small molecules to treat acute and chronic leukemias and myelodysplasia. We are testing several small molecules in patients with relapsed or refractory acute myelogenous leukemia, studying the compounds PKC-412, CEP-701, and MLN-518 that specifically inhibit FLT3. Mutations in the FLT3 gene, which encodes a receptor tyrosine kinase, are thought to confer a poor prognosis in patients with acute myelogenous leukemia. We also have clinical trials under way that test histone deacetylase inhibitors in advanced hematologic malignancies. Our approach is to bring novel therapeutic agents to the forefront in the treatment of patients with acute and chronic leukemia, MDS, and myeloproliferative disorders.
In addition, our group has been focused on the treatment of acute lymphoblastic leukemia (ALL). We are the lead coordinating site for a large clinical trial using dose-intense pediatric-like regimens for adult patients with ALL. We are also testing novel Notch inhibitor molecules for patients with relapsed or refractory T-cell ALL.
Biography
Dr. DeAngelo received his MD and PhD from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.
Select Publications
- Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-4.
- Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, DeAngelo DJ, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-6.
- Haining WN, Cardoso AA, Keezkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol 2005;33:286-94.
- Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005;19:27-30.
- Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib (Iressa) induces myeloid differentiation of acute myeloid leukemia. Blood 2005;106:2841-8.
- Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
- Gong J, Koido S, Kato Y, Tanaka T, Chen D, Jonas A, Galinsky I, DeAngelo DJ, Avigan D, Kufe D, Stone RM. Induction of anti-leukemia cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 2004;28:1303-12.
- Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004;104:1855-8.
- Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, DeAngelo DJ, Galinsky I, Lee SJ. Decision-making and quality-of-life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809-16.
- Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, DeAngelo DJ, Soiffer RJ. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 2003;102:3455-6.
